- Home
- ASPI vs TERN Comparison
ASPI vs TERN Comparison
Compare ASPI & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- TERN
- Stock Information
- Founded
- ASPI 2021
- TERN 2017
- Country
- ASPI United States
- TERN United States
- Employees
- ASPI N/A
- TERN N/A
- Industry
- ASPI Major Chemicals
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- TERN Health Care
- Exchange
- ASPI Nasdaq
- TERN Nasdaq
- Market Cap
- ASPI 330.8M
- TERN 382.2M
- IPO Year
- ASPI 2022
- TERN 2021
- Fundamental
- Price
- ASPI $6.26
- TERN $4.47
- Analyst Decision
- ASPI Strong Buy
- TERN Buy
- Analyst Count
- ASPI 2
- TERN 5
- Target Price
- ASPI $4.50
- TERN $18.30
- AVG Volume (30 Days)
- ASPI 2.0M
- TERN 1.8M
- Earning Date
- ASPI 11-19-2024
- TERN 03-13-2025
- Dividend Yield
- ASPI N/A
- TERN N/A
- EPS Growth
- ASPI N/A
- TERN N/A
- EPS
- ASPI N/A
- TERN N/A
- Revenue
- ASPI $3,383,374.00
- TERN N/A
- Revenue This Year
- ASPI $865.76
- TERN N/A
- Revenue Next Year
- ASPI $700.00
- TERN N/A
- P/E Ratio
- ASPI N/A
- TERN N/A
- Revenue Growth
- ASPI N/A
- TERN N/A
- 52 Week Low
- ASPI $1.86
- TERN $4.32
- 52 Week High
- ASPI $9.33
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ASPI 60.44
- TERN 27.76
- Support Level
- ASPI $4.98
- TERN $4.38
- Resistance Level
- ASPI $5.40
- TERN $4.66
- Average True Range (ATR)
- ASPI 0.53
- TERN 0.27
- MACD
- ASPI 0.20
- TERN -0.07
- Stochastic Oscillator
- ASPI 86.73
- TERN 5.73
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.